Medical equipment and services company Steris (NYSE: STE). met Wall Street’s revenue expectations in Q1 CY2026, with sales up 7.3% year on year to $1.59 billion. Its non-GAAP profit of $2.83 per share was 0.7% below analysts’ consensus estimates.

Is now the time to buy STE? Find out in our full research report (it’s free for active Edge members).

StockStory’s Take

STERIS delivered Q1 results that met Wall Street’s revenue expectations, with the market reacting positively to the company’s performance. Management pointed to steady procedure volume growth in the U.S. and continued expansion in its Healthcare and Life Sciences segments as key drivers. CEO Dan Carestio cited strong service revenue, improved consumables growth, and a stabilizing capital equipment business, while also acknowledging external pressures such as inflation and tariffs. Notably, severe winter weather disruptions impacted procedural volumes and service activity, particularly in the AST (Applied Sterilization Technologies) segment.

Looking forward, STERIS’ guidance for the upcoming year is grounded in expectations for mid- to high-single-digit organic growth, continued strength in service and consumables, and incremental benefits from recent tuck-in acquisitions. Management noted that investments in automation and AI-driven service workflows are expected to support productivity and customer experience. CFO Karen Burton highlighted that tariff headwinds should remain stable, and the company plans to leverage its expanded manufacturing capacity while maintaining a measured approach to share buybacks. Carestio emphasized, “We are committed to partnering with our customers to enable them to meet their procedural growth needs and improve standardization.”

Key Insights from Management’s Remarks

Management attributed quarterly results to strong service and consumables growth, operational resilience in the face of inflation and tariffs, and improved execution in its capital equipment businesses. The market’s positive response was supported by margin expansion despite external cost pressures.

• Service revenue momentum: Robust growth in service, especially within Healthcare, was highlighted as a key contributor, with service revenue rising 12% and helping offset cost inflation and supply chain challenges.
• Consumables share gains: Management credited a 7-8% increase in consumables sales to effective commercial execution and portfolio breadth, which allowed STERIS to capture additional market share among healthcare providers seeking reliable sterilization solutions.
• Capital equipment stabilization: The capital equipment segment showed steady growth, with management noting a reduction in the quarterly volatility seen in recent years. Backlog levels remained solid, even as shipment cycles normalized.
• Tariff and inflation management: While tariffs and inflation continued to impact margins, management cited successful pricing strategies and cost recovery efforts—such as freight recovery pricing—to mitigate these pressures. Incremental tariffs were below expectations due to lower volumes of imported materials.
• AST segment impact from weather: Severe winter storms disrupted operations and customer volumes in the AST segment, resulting in short-term service revenue softness. Management expects underlying demand to recover as weather-related effects subside and med tech customer inventories normalize.

Drivers of Future Performance

STERIS’ outlook for the next year is shaped by expectations for continued U.S. procedure growth, execution on automation initiatives, and integration of recent acquisitions, while balancing known cost headwinds.

• Service and automation investments: Management is investing in multi-year technology upgrades, including AI-powered service workflow improvements in Healthcare and Life Sciences, which are expected to enhance productivity and customer satisfaction while supporting margin expansion.
• Tariff and cost stability: CFO Karen Burton noted that tariff expenses are projected to remain flat, and the company is incorporating moderate assumptions around energy and freight costs. Freight recovery pricing should mitigate most of the volatility in logistics expenses, while raw material inflation is expected to have a limited effect due to its small share of cost of goods sold.
• AST and inventory normalization: The AST segment’s growth is expected to accelerate in the second half of the year as med tech customers work through inventory reductions and weather-related disruptions normalize. Management remains cautious on the pace of recovery but expects underlying procedure volumes to drive demand.

Catalysts in Upcoming Quarters

Looking ahead, the StockStory team will monitor (1) the pace of recovery in the AST segment as med tech customer inventories normalize and weather effects dissipate, (2) execution of automation and AI initiatives in service workflows for Healthcare and Life Sciences, and (3) the integration and revenue contribution from recent tuck-in acquisitions. We will also track management’s ability to maintain margin expansion amid ongoing cost pressures.

STERIS currently trades at $207.19, up from $201.85 just before the earnings. Is the company at an inflection point that warrants a buy or sell? Find out in our full research report (it’s free).

High Quality Stocks for All Market Conditions

ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.

Our AI system flagged Palantir before it ran 1,662%. AppLovin before it ran 753%. Nvidia before it ran 1,178%. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.